Results of a new study suggest that number of LAA lobes may one day be useful as an element of the CHADS2 scoring system for embolic risk in patients with atrial fibrillation.
With the arrival of sophisticated advances in imaging technology, such as three-dimensional echocardiography, we are better able to appreciate the geometric subtleties of the left atrial appendage (LAA) and its contribution to thromboembolic risk in atrial fibrillation (AF).
A recent studyby investigators in Japan and published in Circulation: Cardiovascular Imaging identified LAA structure as a potential congenital risk factor for stroke in AF. Prior to undergoing catheter ablation, 564 patients were prospectively studied with transesophageal echocardiography (TEE). Only 36 (6.4%) had LAA clots at the time of the study. Of those with thrombi, the overwhelming majority (34 patients) had 3 or more LAA lobes and only 2 patients had 2 or fewer LAA lobes.
This study found that complex LAA geometry (3 or more lobes) was the strongest independent risk factor for having a LAA thrombus (multivariate OR 2.5, 95% CI 1.50-1.08, p<.001), followed by CHADS2 score (multivariate OR 1.75, 95% CI 1.24-2.49, p=0.002). This association held true even after adjusting for clinical risk factors and other echocardiographic markers of slow blood flow, such as “smoke” or spontaneous contrast in the LAA. Conversely, of those patients who had 2 or fewer LAA lobes, LAA thrombi formed in only 1%.
Therefore, these findings raise for consideration whether the number of LAA lobes should be considered as part of the calculation of the CHADS2 score when assessing thrombotic risk in patients with AF. While we wait for results of studies to further validate the current findings, clinicians may want to consider the number of LAA lobes when classifying thromboembolic risk in patients with AF.
Yamamoto M, Seo Y, Kawamatsu N, et al. Complex left atrial appendage morphology and left atrial appendage thrombus formation in patients with atrial fibrillation. Circ Cardiovasc Imaging 2014; DOI:10.1161/CIRCIMAGING.113.001317.
Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension
September 9th 2025Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.
Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial
September 2nd 2025At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.